The Emerging Role of Abuse-Deterrent Formulations in Helping to Addressing Opioid Abuse and Misuse
Recorded on August 17, 2017
Sponsored by Daiichi Sankyo, Inc.
Prescription opioid abuse presents a serious and growing public health problem that has posed challenges for healthcare stakeholders, policymakers, and drug manufacturers as they attempt to address this issue. Though there is no single solution to this complex societal problem, the FDA expects abuse-deterrent formulations (ADFs) to play a role in deterring abuse and considers their development to be a public health priority.* In response, some drug manufacturers have devoted significant resources to developing ADFs in an effort to help change the opioid abuse landscape. Sponsored by Daiichi Sankyo, Inc., this webinar will introduce two opioids (one immediate-release and one extended-release) that are formulated to deter abuse.
*Abuse of ADFs is still possible.
Michael Martin, MD, MBA
Medical Director, Pain Therapeutic Area
Daiichi Sankyo, Inc.
This webinar is sponsored, developed and presented by the sponsor. The content of the Science & Innovation Theater Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of the Academy of Managed Care Pharmacy.